Additional Information for Cryptococcus
Alvarez, M., T. Burn, et al. (2009). "The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes." BMC Microbiology 9(51). Buchanan, K. L., and J.W. Murphy (1998). "What makes Cryptococcus neoformans a pathogen?" Emerg Infect Dis 4(1):71-83.
Chayakulkeeree, M. and J. R. Perfect (2006). "Cryptococcosis." Infect Dis Clin North Am 20(3): 507-544, v-vi.
Hajjeh, R. A., L. A. Conn, et al. (1999). "Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group." J Infect Dis 179(2): 449-454.
Heitman, J., T. R. Kozel, et al., Eds. (2011). Cryptococcus: from pathogen to model yeast. Washington, DC, ASM Press.
Kambugu, A., D. B. Meya, et al. (2008). "Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy." Clin Infect Dis 46(11): 1694-1701.
Kidd, S. E., F. Hagen, et al. (2004). "A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada)." Proc Natl Acad Sci U S A 101(49): 17258-17263.
Lawn, S. D., L. Myer, et al. (2005). "Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design." AIDS 19(18): 2141-2148.
Lindsley, M. D., N. Mekha, et al. (2011). "Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis." Clin Infect Dis 53(4): 321-325.
MacDougall, L., S. E. Kidd, et al. (2007). "Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA." Emerg Infect Dis 13(1): 42-50.
McCarthy, K. M., Meintjes, Graeme (2007). "Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients." Southern African Journal of HIV Medicine(28): 25-35.
Meya, D. B., Y. C. Manabe, et al. (2010). "Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings." Clin Infect Dis 51(4): 448-455.
Mirza, S. A., M. Phelan, et al. (2003). "The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000." Clin Infect Dis 36(6): 789-794.
Park, B. J., K. A. Wannemuehler, et al. (2009). "Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS." AIDS 23(4): 525-530.
Powderly, W. G., D. Finkelstein, et al. (1995). "A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group." N Engl J Med 332(11): 700-705.
Singh, N., M. J. Barnish, et al. (1996). "Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial." Clin Infect Dis 23(6): 1282-1286.